
The advancement of antibody discovery technologies like hybridoma, display libraries, Single B-cell sorting/sequencing, and computational modeling has led to the production of thousands of monoclonal antibodies (mAbs). However, identifying the "best-in-class" antibody therapeutics requires rapid assessment using high throughput (HTP) processes.
Recombinant antibodies are monoclonal antibodies produced in vitro through synthetic genes and antibody fragments, instead of using hybridomas. They can take several different formats, such as full-length immunoglobulins (Ig), monovalent antibody fragments such as single-chain fragment variable (scFv) and fragment antigen-binding (Fab), and multimeric diabodies (dimeric scFvs) or triabodies (trimeric scFvs).
A VHH antibody is the antigen binding fragment of heavy chain only antibodies. They are derived from the immune system of camelids such as alpacas. As they are highly stable and much smaller than traditional antibodies, VHH antibodies are ideal for a wide range of applications, including diagnostic tests, therapeutics, and research tools.
High-throughput (HTP) recombinant antibody production is the rapid generation of large numbers of recombinant antibodies. This enables the acceleration of research, paving the way towards clinical trials, as well as streamlining the discovery and development processes.
Biointron’s 2-week high-throughput recombinant antibody production is the leading gene-to-antibody workflow in the industry. By integrating our recombinant protein expression service, we ensure the efficient and scalable production of antibodies tailored to meet diverse research and therapeutic needs. We offer the flexibility to rapidly express large amounts of antibodies at varying scales using HEK293 or CHO cells, which are known for efficient recombinant protein production. As part of this approach, our mammalian protein expression service provides an optimized platform for generating high-quality antibodies with superior functionality.
VHH half extension mechanisms like Fc fusion, albumin binding, and PEGylation to……
Learn how multivalent and bispecific VHH antibodies are engineered, their advant……
April 2026 activity saw consolidation in the ADC space, continued expansion of n……
Read on for key trends talked about during the conference: Antibody Therapeutics……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



